Viewing Study NCT05565092

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 3:21 PM
Ignite Modification Date: 2026-02-03 @ 2:50 PM
Study NCT ID: NCT05565092
Status: TERMINATED
Last Update Posted: 2025-01-13
First Post: 2022-09-15
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Study of ALXN1820 in Adult Participants With Sickle Cell Disease
Sponsor: Alexion Pharmaceuticals, Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Sickle Cell Disease (SCD) View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Sickle Cell Disease View
None ALXN1820 View
None SCD View